# Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma

> **NCT00002649** · PHASE3 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 206 (actual)

## Conditions studied

- Recurrent Adult Burkitt Lymphoma
- Recurrent Adult Diffuse Large Cell Lymphoma
- Recurrent Adult Diffuse Mixed Cell Lymphoma
- Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
- Recurrent Adult Immunoblastic Large Cell Lymphoma
- Recurrent Grade 1 Follicular Lymphoma
- Recurrent Grade 2 Follicular Lymphoma
- Recurrent Grade 3 Follicular Lymphoma

## Interventions

- **BIOLOGICAL:** aldesleukin
- **BIOLOGICAL:** filgrastim
- **DRUG:** cyclophosphamide
- **DRUG:** etoposide
- **RADIATION:** radiation therapy
- **PROCEDURE:** peripheral blood stem cell transplantation
- **PROCEDURE:** bone marrow ablation with stem cell support

## Key facts

- **NCT ID:** NCT00002649
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1995-05
- **Primary completion:** 2006-11
- **Final completion:** —
- **Target enrollment:** 206 (ACTUAL)
- **Last updated:** 2013-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002649, "Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00002649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*